University of Naples 'Federico II', Department of Chemical Sciences, Complesso Universitario di Monte Sant'Angelo, Via Cintia 46, 80126 Naples, Italy.
University of Naples 'Federico II', Department of Chemical Sciences, Complesso Universitario di Monte Sant'Angelo, Via Cintia 46, 80126 Naples, Italy.
Drug Discov Today. 2020 Aug;25(8):1528-1534. doi: 10.1016/j.drudis.2020.06.013. Epub 2020 Jun 18.
Here, we highlight recent findings on the urokinase plasminogen activator (uPA)/uPA receptor (uPAR) system that suggest its potential role as a main orchestrator of fatal progression to pulmonary, kidney, and heart failure in patients with coronavirus. Patients with prolonged background inflammation can present aberrant inflammatory reactions, well recognized as the main factors that can result in death and probably sustained by a dysregulated uPA/uPAR system. SuPAR, the soluble form of uPAR, represents a biomarker of disease progression, and its levels correlate well with comorbidities associated with the death of patients with coronavirus. New drugs that regulate the uPA/uPAR system could help treat the severe complications of highly pathogenic human coronaviruses (hCoVs), including pandemic coronavirus 2019 (COVID-19).
在这里,我们强调了尿激酶型纤溶酶原激活物(uPA)/uPA 受体(uPAR)系统的最新发现,这些发现表明其可能作为冠状病毒患者发生致命性肺、肾和心力衰竭进展的主要协调因子。具有长期背景炎症的患者可能会出现异常炎症反应,这是公认的导致死亡的主要因素,可能由失调的 uPA/uPAR 系统维持。suPAR 是 uPAR 的可溶性形式,是疾病进展的生物标志物,其水平与与冠状病毒患者死亡相关的合并症密切相关。调节 uPA/uPAR 系统的新药可能有助于治疗高致病性人类冠状病毒(hCoVs)的严重并发症,包括 2019 年冠状病毒病(COVID-19)。